Senator Bernie Sanders Pushes to Lower Ozempic Drug Prices

By
Hélène Duval
1 min read
⚠️ Heads up: this article is from our "experimental era" — a beautiful mess of enthusiasm ✨, caffeine ☕, and user-submitted chaos 🤹. We kept it because it’s part of our journey 🛤️ (and hey, everyone has awkward teenage years 😅).

Senator Bernie Sanders is seeking a meeting with Novo Nordisk A/S’s top executive to address the high cost of the blockbuster drug Ozempic, particularly in relation to GLP-1 drugs for diabetes and obesity. The Vermont independent is contemplating holding hearings on the pricing of these drugs and hopes to have a personal conversation with Novo's CEO, Lars Fruergaard Jørgensen, before making any decisions. This move has ignited controversy over the pricing of crucial medications for chronic conditions and signals potential action to combat rising drug costs in the healthcare market.

You May Also Like

This article is submitted by our user under the News Submission Rules and Guidelines. The cover photo is computer generated art for illustrative purposes only; not indicative of factual content. If you believe this article infringes upon copyright rights, please do not hesitate to report it by sending an email to us. Your vigilance and cooperation are invaluable in helping us maintain a respectful and legally compliant community.

Subscribe to our Newsletter

Get the latest in enterprise business and tech with exclusive peeks at our new offerings

We use cookies on our website to enable certain functions, to provide more relevant information to you and to optimize your experience on our website. Further information can be found in our Privacy Policy and our Terms of Service . Mandatory information can be found in the legal notice